Cargando…
BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells()
Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats r...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548338/ https://www.ncbi.nlm.nih.gov/pubmed/28797938 http://dx.doi.org/10.1016/j.tranon.2017.07.003 |
_version_ | 1783255823244328960 |
---|---|
author | Xing, Jieyu Lin, Limin Li, Jing Liu, Jiayu Zhou, Changhua Pan, Haitao Shu, Rui Dong, Bin Cao, Donglin Li, Qing Wang, Zhong |
author_facet | Xing, Jieyu Lin, Limin Li, Jing Liu, Jiayu Zhou, Changhua Pan, Haitao Shu, Rui Dong, Bin Cao, Donglin Li, Qing Wang, Zhong |
author_sort | Xing, Jieyu |
collection | PubMed |
description | Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats require extensive processing to obtain heterodimeric bispecific antibodies. In this study, we describe a bispecific antibody, BiHC (bispecific Her2-CD3 antibody), constructed with a single-domain anti-Her2 and a single-chain Fv (variable fragment) of anti-CD3 in an IgG-like format. In contrast to most IgG-like BsAbs, the two arms in BiHC have different molecular weights, making it easier to separate hetero- or homodimers. BiHC can be expressed in Escherichia coli and purified via Protein A affinity chromatography. The purified BiHC can recruit T cells and induce specific cytotoxicity of Her2-expressing tumor cells in vitro. The BiHC can also efficiently inhibit the tumor growth in vivo. Thus, BiHC is a promising candidate for the treatment of Her2-positive cancers. |
format | Online Article Text |
id | pubmed-5548338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55483382017-08-14 BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() Xing, Jieyu Lin, Limin Li, Jing Liu, Jiayu Zhou, Changhua Pan, Haitao Shu, Rui Dong, Bin Cao, Donglin Li, Qing Wang, Zhong Transl Oncol Original article Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats require extensive processing to obtain heterodimeric bispecific antibodies. In this study, we describe a bispecific antibody, BiHC (bispecific Her2-CD3 antibody), constructed with a single-domain anti-Her2 and a single-chain Fv (variable fragment) of anti-CD3 in an IgG-like format. In contrast to most IgG-like BsAbs, the two arms in BiHC have different molecular weights, making it easier to separate hetero- or homodimers. BiHC can be expressed in Escherichia coli and purified via Protein A affinity chromatography. The purified BiHC can recruit T cells and induce specific cytotoxicity of Her2-expressing tumor cells in vitro. The BiHC can also efficiently inhibit the tumor growth in vivo. Thus, BiHC is a promising candidate for the treatment of Her2-positive cancers. Neoplasia Press 2017-08-07 /pmc/articles/PMC5548338/ /pubmed/28797938 http://dx.doi.org/10.1016/j.tranon.2017.07.003 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Xing, Jieyu Lin, Limin Li, Jing Liu, Jiayu Zhou, Changhua Pan, Haitao Shu, Rui Dong, Bin Cao, Donglin Li, Qing Wang, Zhong BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() |
title | BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() |
title_full | BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() |
title_fullStr | BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() |
title_full_unstemmed | BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() |
title_short | BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells() |
title_sort | bihc, a t-cell–engaging bispecific recombinant antibody, has potent cytotoxic activity against her2 tumor cells() |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548338/ https://www.ncbi.nlm.nih.gov/pubmed/28797938 http://dx.doi.org/10.1016/j.tranon.2017.07.003 |
work_keys_str_mv | AT xingjieyu bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT linlimin bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT lijing bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT liujiayu bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT zhouchanghua bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT panhaitao bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT shurui bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT dongbin bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT caodonglin bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT liqing bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells AT wangzhong bihcatcellengagingbispecificrecombinantantibodyhaspotentcytotoxicactivityagainsther2tumorcells |